News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Shares of SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, tumbled on Thursday after the announcement of the pricing of a share offering of 12 million shares and accompanying warrants at $0.75 per share, to raise $9 million.
Currently, SELLAS's stock is falling 35.4%, to $0.5850 on a volume of 2,350,522 from its previous close of $0.9055. It has traded between $0.5801 and $4.13 in the past 52-week period.
The accompanying warrants will expire in five years after its issuance.
The offering will close on or about January 8, 2024, the company said in a statement.
A.G.P./Alliance Global Partners acts as sole placement agent for this offering.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
